

Remarks


Claims 1-5, 7, and 10 are pending in this application. Claims 1-5, 7, and 10 have been amended. Claims 6, 8, 9, and 11 have been cancelled. No new matter has been added.

The notification of missing requirements states that an English translation of the specification must be furnished. This requirement is met in this preliminary amendment by the submission of a substitute specification in accordance with 37 C.F.R. 1.125. The substitute specification is provided in clean form as well as in marked-up form showing changes, and contains no new matter relative to the original German specification (PCT/EP2003/006896). The amendments shown in the marked-up copy of the English substitute specification are to indicate text which was inadvertently omitted from the originally-filed English translation of the original German specification and is now being inserted to cure the omission.

The present amendments make the claims closer to the usual US form, for the purpose of facilitating prosecution in the US PTO.

In view of the above amendments, the claims of this application are deemed to be of a form which is amenable to prosecution. Examination in due course is accordingly requested.

Respectfully submitted,



William F. Gray
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175

Reg. No.: 31018
Phone: (203) 812-2712
Date: 5 August 2005